PE20120015A1 - Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico - Google Patents
Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeuticoInfo
- Publication number
- PE20120015A1 PE20120015A1 PE2011000159A PE2011000159A PE20120015A1 PE 20120015 A1 PE20120015 A1 PE 20120015A1 PE 2011000159 A PE2011000159 A PE 2011000159A PE 2011000159 A PE2011000159 A PE 2011000159A PE 20120015 A1 PE20120015 A1 PE 20120015A1
- Authority
- PE
- Peru
- Prior art keywords
- perbb3
- therapeutic agent
- predicting
- response
- systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
REFERIDA A UN METODO PARA TRATAR A UN PACIENTE QUE TIENE UN TUMOR NEOPLASICO QUE COMPRENDE: A) OBTENER UNA MUESTRA DEL TUMOR; B) DETERMINAR EL NIVEL DE pErbB3 EN LA MUESTRA Y DEPENDIENDO DE LA CANTIDAD DE pErbB3 EN PORCENTAJE DE UN CULTIVO DE CELULAS ACHN SEGUIDO POR EL CULTIVO DE 20-24 HORAS EN MEDIO LIBRE DE SUERO; C) ADMINISTRAR AL MENOS UN AGENTE TERAPEUTICO ANTINEOPLASICO AL PACIENTE TAL COMO ANTICUERPO ANTI-ErbB3 SI EL NIVEL DE pErbB3 NO ES MENOR QUE 50% O UN ANTICUERPO DIFERENTE CUANDO EL NIVEL DE pErbB3 ES MENOR A 50%. DICHO METODO ES UTIL EN EL TRATAMIENTO DE TUMOR DE COLON, PULMON, RECTO, CEREBRO, MAMAS, RINON, ESTOMAGO, ENTRE OTROS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18905308P | 2008-08-15 | 2008-08-15 | |
US19470208P | 2008-09-30 | 2008-09-30 | |
US20820609P | 2009-02-20 | 2009-02-20 | |
US17036709P | 2009-04-17 | 2009-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120015A1 true PE20120015A1 (es) | 2012-01-26 |
Family
ID=41228727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000159A PE20120015A1 (es) | 2008-08-15 | 2009-08-17 | Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico |
Country Status (24)
Country | Link |
---|---|
US (4) | US8623592B2 (es) |
EP (1) | EP2318548B1 (es) |
JP (1) | JP2012500008A (es) |
KR (1) | KR20110044905A (es) |
CN (1) | CN102224255A (es) |
AU (1) | AU2009281721A1 (es) |
BR (1) | BRPI0917871A2 (es) |
CA (1) | CA2732658A1 (es) |
CO (1) | CO6341654A2 (es) |
CR (1) | CR20110128A (es) |
DO (1) | DOP2011000054A (es) |
EA (1) | EA022884B1 (es) |
EC (1) | ECSP11010872A (es) |
ES (1) | ES2433424T3 (es) |
HK (1) | HK1155782A1 (es) |
IL (1) | IL210865A (es) |
MA (1) | MA32630B1 (es) |
MX (1) | MX2011001764A (es) |
NZ (1) | NZ591137A (es) |
PE (1) | PE20120015A1 (es) |
SV (1) | SV2011003840A (es) |
UA (1) | UA104868C2 (es) |
WO (1) | WO2010019952A2 (es) |
ZA (1) | ZA201100921B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
US8927694B2 (en) * | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
PL2544680T3 (pl) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
SG185366A1 (en) | 2010-05-04 | 2012-12-28 | Merrimack Pharmaceuticals Inc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
WO2011159904A1 (en) * | 2010-06-17 | 2011-12-22 | The Trustees Of The University Of Pennsylvania | Methods for predicting cellular signaling responses to combinatorial stimuli |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2635604B1 (en) | 2010-11-01 | 2016-11-30 | Symphogen A/S | Pan-her antibody composition |
SG193006A1 (en) | 2011-03-02 | 2013-10-30 | Berg Llc | Interrogatory cell-based assays and uses thereof |
EA201300996A1 (ru) | 2011-03-11 | 2014-01-30 | Мерримак Фармасьютикалс, Инк. | Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы |
JP5588086B2 (ja) | 2011-04-19 | 2014-09-10 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗IGF‐1R抗体および抗ErbB3抗体 |
US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
EP2530462A1 (en) * | 2011-06-03 | 2012-12-05 | Merrimack Pharmaceuticals, Inc. | Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof |
AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
MX357391B (es) * | 2011-09-30 | 2018-07-06 | Regeneron Pharma | Anticuerpos anti-erbb3 y usos de los mismos. |
CN103959065B (zh) * | 2011-10-06 | 2018-07-17 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
AU2012335543C1 (en) | 2011-11-09 | 2017-12-14 | Beijing Cotimes Biotech Co., Ltd., | HER3 antibodies and uses thereof |
CN104160400A (zh) * | 2011-12-16 | 2014-11-19 | 克里帝奥成果技术公司 | 用于确定癌症治疗的可编程细胞模型 |
CN108048521B (zh) * | 2012-04-02 | 2022-05-27 | 博格有限责任公司 | 基于细胞的探询式分析及其应用 |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
CA2876636C (en) * | 2012-06-13 | 2022-09-13 | Medimmune, Llc | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
KR101430309B1 (ko) * | 2012-11-14 | 2014-08-13 | 이선우 | 바이오 3d 모델링 장치 |
ES2971536T3 (es) * | 2012-11-21 | 2024-06-05 | Janssen Biotech Inc | Anticuerpos biespecíficos egfr/c-met |
US10489717B2 (en) | 2013-01-03 | 2019-11-26 | Aetna, Inc. | System and method for pharmacovigilance |
US11424040B2 (en) * | 2013-01-03 | 2022-08-23 | Aetna Inc. | System and method for pharmacovigilance |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
KR20140093347A (ko) * | 2013-01-15 | 2014-07-28 | 삼성전자주식회사 | 항 c-Met 항체 처리에 의해 부작용을 유발하는 유전자 및 이를 이용한 약물 스크리닝 방법 |
JP2016535079A (ja) * | 2013-09-30 | 2016-11-10 | 第一三共株式会社 | 核酸生体マーカー及びその使用 |
WO2015048804A2 (en) * | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Co., Ltd. | Protein biomarker and uses thereof |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
KR102456088B1 (ko) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
US20150285817A1 (en) * | 2014-04-08 | 2015-10-08 | Biodesix, Inc. | Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
US10482385B2 (en) | 2014-09-11 | 2019-11-19 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
CN107750165A (zh) * | 2015-04-17 | 2018-03-02 | 梅里麦克制药股份有限公司 | 借助塞里班土单抗的组合治疗 |
GB201508841D0 (en) * | 2015-05-22 | 2015-07-01 | Isis Innovation | Treatment |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
JP6382459B1 (ja) * | 2015-06-15 | 2018-08-29 | ナントミクス,エルエルシー | 細胞系ゲノミクスからの薬物応答の患者特異的予測のためのシステムおよび方法 |
JP6836586B2 (ja) * | 2015-09-29 | 2021-03-03 | エイチティージー モレキュラー ダイアグノスティクス, インコーポレイテッド | びまん性大細胞型b細胞性リンパ腫(dlbcl)を亜型決定するための方法 |
EP3429623A1 (en) | 2016-03-15 | 2019-01-23 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
EP3542290B1 (en) * | 2016-11-17 | 2024-01-03 | NantBio, Inc. | Validation of inferred anticancer pathways |
JP7404648B2 (ja) | 2019-04-25 | 2023-12-26 | 富士通株式会社 | 治療薬提示方法、治療薬提示装置、及び治療薬提示プログラム |
US20230088271A1 (en) * | 2020-02-28 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Determining Spatial Accumulation of Signaling Molecules Within Tissue Samples |
WO2021240263A1 (en) | 2020-05-26 | 2021-12-02 | Insilico Medicine Ip Limited | Biological data signatures of aging and methods of determining a biological aging clock |
WO2022058980A1 (en) | 2020-09-21 | 2022-03-24 | Insilico Medicine Ip Limited | Methylation data signatures of aging and methods of determining a methylation aging clock |
CN113049249A (zh) * | 2020-12-31 | 2021-06-29 | 山东科技大学 | 一种电机轴承故障诊断方法及系统 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5344760A (en) * | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
US6983227B1 (en) * | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
DK0896586T4 (en) * | 1996-03-27 | 2015-08-24 | Genentech Inc | ErbB3 antibodies. |
CN1202247C (zh) * | 1996-07-12 | 2005-05-18 | 基因技术股份有限公司 | 嵌合异源多亚基粘附素 |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US20020002276A1 (en) * | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
JP2002515511A (ja) | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
PL202369B1 (pl) * | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
DE60139768D1 (de) * | 2000-05-19 | 2009-10-15 | Genentech Inc | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine k |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6871171B1 (en) * | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
EP1228766A1 (en) * | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2003011897A1 (en) * | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
EP1421113A4 (en) * | 2001-08-03 | 2005-04-13 | Commw Scient Ind Res Org | SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
IL161430A0 (en) * | 2001-10-19 | 2004-09-27 | Pharma Mar Sa | Pharmaceutical compositions containing ecteinascidin 743 |
US7415359B2 (en) * | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
EP1495123B1 (en) * | 2002-03-26 | 2013-10-30 | Zensun (Shanghai) Science and Technology Limited | Erbb3 based methods and compositions for treating neoplasms |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
WO2004000102A2 (en) * | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
BRPI0408928A (pt) * | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
CA2534898A1 (en) * | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US20070059785A1 (en) * | 2003-08-15 | 2007-03-15 | Smithkline Beecham Corporation | Biomarkers in cancer |
CN100559203C (zh) * | 2003-09-19 | 2009-11-11 | Nxp股份有限公司 | 包括秘密的子模块的电子电路 |
US8554486B2 (en) * | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
BRPI0508286B8 (pt) * | 2004-03-31 | 2021-05-25 | Dana Farber Cancer Inst Inc | método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores |
EP1778270A4 (en) * | 2004-05-05 | 2009-09-02 | Merrimack Pharmaceuticals Inc | BIS-SPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY |
ES2553264T3 (es) * | 2004-05-27 | 2015-12-07 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
WO2005121380A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
RU2410438C2 (ru) * | 2004-08-06 | 2011-01-27 | Дженентек, Инк. | Анализы и способы, использующие биомаркеры |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
US20060136139A1 (en) * | 2004-10-12 | 2006-06-22 | Elcock Adrian H | Rapid computational identification of targets |
WO2006044748A2 (en) | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
EP1913160A2 (en) * | 2005-07-29 | 2008-04-23 | Bayer Healthcare LLC | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
CA2624613A1 (en) | 2005-10-05 | 2007-04-12 | Astrazeneca Uk Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009532393A (ja) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ErbB受容体由来ペプチド断片 |
DK2032982T3 (da) | 2006-05-05 | 2012-11-05 | Univ Yale | Anvendelse af subcellulær lokaliseringsprofiler som prognostiske eller prædiktive indikatorer |
EP2047262A4 (en) * | 2006-07-13 | 2011-03-16 | Univ Yale | PROGNOSTIC METHODS OF CANCER FROM THE SUBCELLULAR LOCATION OF BIOMARKERS |
EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
SI2129396T1 (sl) * | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CL2008000614A1 (es) | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her. |
DK2076289T3 (da) * | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
-
2009
- 2009-08-17 US US13/058,687 patent/US8623592B2/en not_active Expired - Fee Related
- 2009-08-17 CN CN2009801404673A patent/CN102224255A/zh active Pending
- 2009-08-17 KR KR1020117005954A patent/KR20110044905A/ko not_active Application Discontinuation
- 2009-08-17 EA EA201100373A patent/EA022884B1/ru not_active IP Right Cessation
- 2009-08-17 JP JP2011523216A patent/JP2012500008A/ja active Pending
- 2009-08-17 ES ES09791584T patent/ES2433424T3/es active Active
- 2009-08-17 WO PCT/US2009/054051 patent/WO2010019952A2/en active Application Filing
- 2009-08-17 PE PE2011000159A patent/PE20120015A1/es not_active Application Discontinuation
- 2009-08-17 EP EP09791584.7A patent/EP2318548B1/en not_active Revoked
- 2009-08-17 AU AU2009281721A patent/AU2009281721A1/en not_active Abandoned
- 2009-08-17 CA CA2732658A patent/CA2732658A1/en not_active Abandoned
- 2009-08-17 UA UAA201101792A patent/UA104868C2/uk unknown
- 2009-08-17 NZ NZ591137A patent/NZ591137A/xx not_active IP Right Cessation
- 2009-08-17 MX MX2011001764A patent/MX2011001764A/es active IP Right Grant
- 2009-08-17 BR BRPI0917871A patent/BRPI0917871A2/pt not_active IP Right Cessation
-
2010
- 2010-02-17 US US12/707,521 patent/US20110027291A1/en not_active Abandoned
-
2011
- 2011-01-25 IL IL210865A patent/IL210865A/en not_active IP Right Cessation
- 2011-02-04 ZA ZA2011/00921A patent/ZA201100921B/en unknown
- 2011-02-14 DO DO2011000054A patent/DOP2011000054A/es unknown
- 2011-02-15 SV SV2011003840A patent/SV2011003840A/es unknown
- 2011-02-16 CO CO11018669A patent/CO6341654A2/es not_active Application Discontinuation
- 2011-03-04 EC EC2011010872A patent/ECSP11010872A/es unknown
- 2011-03-10 CR CR20110128A patent/CR20110128A/es unknown
- 2011-03-11 MA MA33695A patent/MA32630B1/fr unknown
- 2011-09-21 HK HK11109930.1A patent/HK1155782A1/xx not_active IP Right Cessation
-
2014
- 2014-01-06 US US14/148,379 patent/US20140127238A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,664 patent/US20170307631A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170307631A1 (en) | 2017-10-26 |
DOP2011000054A (es) | 2011-04-30 |
WO2010019952A2 (en) | 2010-02-18 |
KR20110044905A (ko) | 2011-05-02 |
HK1155782A1 (en) | 2012-05-25 |
IL210865A0 (en) | 2011-04-28 |
US8623592B2 (en) | 2014-01-07 |
CR20110128A (es) | 2011-09-27 |
CA2732658A1 (en) | 2010-02-18 |
ZA201100921B (en) | 2014-06-25 |
ES2433424T3 (es) | 2013-12-11 |
MA32630B1 (fr) | 2011-09-01 |
EP2318548A2 (en) | 2011-05-11 |
AU2009281721A1 (en) | 2010-02-18 |
US20140127238A1 (en) | 2014-05-08 |
NZ591137A (en) | 2012-10-26 |
EP2318548B1 (en) | 2013-10-16 |
CN102224255A (zh) | 2011-10-19 |
IL210865A (en) | 2014-04-30 |
SV2011003840A (es) | 2011-07-06 |
BRPI0917871A2 (pt) | 2017-06-20 |
CO6341654A2 (es) | 2011-11-21 |
EA201100373A1 (ru) | 2011-08-30 |
US20110159513A1 (en) | 2011-06-30 |
JP2012500008A (ja) | 2012-01-05 |
US20110027291A1 (en) | 2011-02-03 |
WO2010019952A3 (en) | 2010-06-24 |
EA022884B1 (ru) | 2016-03-31 |
MX2011001764A (es) | 2011-05-19 |
ECSP11010872A (es) | 2011-09-30 |
UA104868C2 (uk) | 2014-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120015A1 (es) | Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico | |
MX2009005849A (es) | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. | |
SG10201901076WA (en) | Methods of treating alzheimer's disease | |
EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
ATE461294T1 (de) | Brustkrebsdiagnoseverfahren | |
EA201500156A3 (ru) | Доставка антител посредством модульного домена распознавания | |
MY163057A (en) | Means and methods for trating dlblcl | |
BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
ATE455463T1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
DE602006018709D1 (de) | Estergebundene geminitensidverbindungen zur verwendung in der gentherapie | |
EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
GB2467467C (en) | TAZ/WWTR1 for diagnosis and treatment of cancer | |
MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
AR081209A1 (es) | Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11 | |
ATE555814T1 (de) | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 | |
EP2957642A3 (en) | Microrna patterns for the diagnosis, prognosis and treatment of melanoma | |
WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
EA202092156A1 (ru) | Модифицированные олигонуклеотиды и способы применения в лечении таупатий |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |